Article originally published in PLC Life Sciences Handbook 2012

M&A in the life sciences sector has remained robust, driven by factors such as:

  • „„ The need to replenish shrinking product pipelines.
  • „„ The need to maintain revenues as patents on top-selling
  • products expire.
  • „„ The strategic diversification of business lines.
  • „„ Expansion into emerging markets.

Unique features of research, development and commercialisation of products and technologies in the life sciences sector give rise to a multitude of issues across a broad range of legal and commercial fields. Therefore, it is essential for life sciences M&A teams to include counsel who are experienced in identifying and resolving sector-specific issues across a range of practice areas. This will ensure smooth implementation of the commercial deal.

This article illustrates how a complex and evolving legal and regulatory environment gives rise to unique challenges for those engaged in European M&A in the life sciences sector, by analysing a hypothetical M&A. In particular, it examines:

  • „„ A life sciences M&A case study.
  • „„ Due diligence and its impact.
  • „„ Intellectual property issues.
  • „„ Structuring the deal.
  • „„ European competition laws.
  • „„ Anti-corruption laws.
  • „„ Employment issues.
  • „„ Tax issues.

Read the complete article here